Inozyme Pharma
Clinical trials sponsored by Inozyme Pharma, explained in plain language.
-
New hope for babies: drug targets rare genetic disorder that hardens arteries
Disease control OngoingThis study tests a new medicine called INZ-701 in babies up to 1 year old who have a rare genetic condition (ENPP1 deficiency) that causes severe hardening of the arteries and bone problems. The goal is to see if the drug can raise a key substance in the blood, improve survival, …
Phase: PHASE3 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for babies with rare calcification disease: first drug trial launches
Disease control OngoingThis study tests a new drug called INZ-701 in up to 16 infants (up to 1 year old) with rare genetic conditions (ENPP1 or ABCC6 deficiency) that cause dangerous calcium buildup in arteries and other problems. The main goal is to check the drug's safety and how the body handles it,…
Phase: PHASE1 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC